Literature DB >> 29160724

Exosome Treatment of Bronchopulmonary Dysplasia: How Pure Should Your Exosome Preparation Be?

Maurizio Muraca1, Patrizia Zaramella1, Andrea Porzionato1, Eugenio Baraldi1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29160724     DOI： 10.1164/rccm.201709-1851LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  3 in total

1.  Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6.

Authors:  Sushma Chaubey; Sam Thueson; Devasena Ponnalagu; Mohammad Afaque Alam; Ciprian P Gheorghe; Zubair Aghai; Harpreet Singh; Vineet Bhandari
Journal:  Stem Cell Res Ther       Date:  2018-06-26       Impact factor: 6.832

2.  Innate immunity ascertained from blood and tracheal aspirates of preterm newborn provides new clues for assessing bronchopulmonary dysplasia.

Authors:  Patrizia Zaramella; Fabio Munari; Matteo Stocchero; Barbara Molon; Daniel Nardo; Elena Priante; Francesca Tosato; Luca Bonadies; Antonella Viola; Eugenio Baraldi
Journal:  PLoS One       Date:  2019-09-04       Impact factor: 3.240

Review 3.  Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Bronchopulmonary Dysplasia.

Authors:  Yufeng Xi; Rong Ju; Yujia Wang
Journal:  Front Pediatr       Date:  2022-04-04       Impact factor: 3.569
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.